Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 82
- Registration Number
- NCT03033914
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
- Conditions
- Solitary Fibrous Tumors
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Italian Sarcoma Group
- Target Recruit Count
- 23
- Registration Number
- NCT03023124
- Locations
- 🇮🇹
Nuovo Ospedale di Prato, Prato, Firenze, Italy
🇮🇹Policlinico Universitario Campus Biomedico, Roma, RM, Italy
🇮🇹IRCCS Istituto ortopedico Rizzoli, Bologna, Italy
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- Conditions
- Alveolar Soft Part SarcomaSynovial SarcomaSoft-Tissue SarcomaLeiomyosarcoma
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Advenchen Laboratories, LLC
- Target Recruit Count
- 325
- Registration Number
- NCT03016819
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California Los Angeles, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2016-12-29
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 110
- Registration Number
- NCT03004833
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
- Conditions
- Hodgkin Disease
- Interventions
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 59
- Registration Number
- NCT02979522
- Locations
- 🇧🇷
ICr - Instituto da Crianca - HCFMUSP, Sao Paulo, Brazil
🇮🇹Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia, Roma, Italy
🇧🇷Hospital Santa Marcelina, Sao Paulo, Brazil
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents
- Conditions
- Classical Hodgkins Lymphoma in Children and Adolescents.
- Interventions
- First Posted Date
- 2016-06-13
- Last Posted Date
- 2016-06-14
- Lead Sponsor
- GALIA AVRAHAMI
- Target Recruit Count
- 2200
- Registration Number
- NCT02797717
- Locations
- 🇮🇱
Schneider children's medical center, Petach-Tikva, Israel
HD21 for Advanced Stages
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2016-01-22
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 1500
- Registration Number
- NCT02661503
- Locations
- 🇩🇪
University Hospital of Cologne, Cologne, Germany
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 182
- Registration Number
- NCT02545075
- Locations
- 🇨🇳
Local Institution, Shanghai, China
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT02505269
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
- Conditions
- Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2022-08-19
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 170
- Registration Number
- NCT02292979
- Locations
- 🇳🇱
Reinier De Graaf Gasthuis, Delft, Netherlands
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇫🇷CHU de Clermont-Ferrand, Clermont-Ferrand, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.